Neovacs

Regulatory Filings • Jan 19, 2015

PRESS RELEASE PRESS RELEASE PRESS RELEASE

NEOVACS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE

Paris, January 19, 2015 – NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that the Company will be presenting at the BIO CEO & Investor Conference to be held in New York on February 9-10, 2015.

The 17th Annual BIO CEO & Investor Conference attracts over 750 investors and takes place at the Waldorf Astoria, New York. A select number of biotech CEOs are given the opportunity to introduce their companies, technology and development programs.

Miguel Sieler, CEO of Neovacs, will present on February 9, 2015 at 9:30 am E.T.

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Contacts

NEOVACS

Nathalie Trépo +33 (0)1 53 10 93 00 ntrepo@neovacs.com

Press – Financial Communications- Publicis Stéphanie Tabouis +33 (0) 1 44 82 46 35 stéphanie.tabouis@consultants.publicis.fr

Investor Relations – Financial Communications Germany – MC Services Raimund Gabriel +49-89-210228-30 Raimund.Gabriel@mc-services.eu

Press – U.S. Inquiries – The Ruth Group Melanie Sollid-Penton 1.646.536.7023 msollid@theruthgroup.com